Kestra Medical Technologies reported first-quarter fiscal 2027 results ending July 31, 2026. Revenue increased 60% to $31.0 million, while gross margin expanded to 56.5%. The company raised its full-year FY27 revenue guidance to $141 million from the previous estimate of $137 million. GAAP net loss widened to $44.1 million compared to $25.8 million in the prior year period, driven by increased operating expenses and a $6.3 million loss on debt extinguishment. Cash and investments totaled $244.7 million as of July 31, 2026. Kestra Medical Technologies operates in the wearable medical device and digital healthcare industry.

Kestra Medical Technologies, Ltd. entered into a $200.0 million five-year senior secured term loan facility with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP. The facility is divided into four tranches: a $75.0 million Tranche A loan (funded on July 10, 2020, 26), a $25.0 million Tranche B loan, a $50.0 million Tranche C loan (contingent on revenue), and a $50.0 million uncommitted Tranche D loan for acquisitions. Tranche A net proceeds of approximately $20.0 million were used to repay the Prior Loan Agreement with Perceptive Credit Holdings IV, LP and to fund general corporate and working capital requirements. The term loans mature on July 10, 2031, and bear interest at a variable rate of 5.50% plus three-month SOFR (floor of 3.25%). Kestra Medical Technologies, Ltd. is a medical technology company that develops and manufactures medical devices for the treatment of cardiac and cardiac-related issues.